Jpmorgan Chase & CO Nautilus Biotechnology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35,603 shares of NAUT stock, worth $63,373. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,603
Previous 37,617
5.35%
Holding current value
$63,373
Previous $88,000
14.77%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NAUT
# of Institutions
86Shares Held
64.3MCall Options Held
1.9KPut Options Held
100-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA16.3MShares$29 Million24.08% of portfolio
-
Perceptive Advisors LLC New York, NY12.6MShares$22.4 Million0.94% of portfolio
-
Cercano Management LLC Bellevue, WA7.17MShares$12.8 Million0.51% of portfolio
-
Madrona Venture Group, LLC6.02MShares$10.7 Million23.0% of portfolio
-
Black Rock Inc. New York, NY3.83MShares$6.81 Million0.0% of portfolio
About Nautilus Biotechnology, Inc.
- Ticker NAUT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,663,000
- Market Cap $222M
- Description
- Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...